The stock price of Gossamer Bio Inc (NASDAQ: GOSS) has jumped by 8.75 compared to previous close of 1.13. Despite this, the company has seen a fall of -5.47% in its stock price over the last five trading days. seekingalpha.com reported 2025-02-13 that Gossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far produced encouraging Phase 2 data and has an ongoing Phase 3 PROSERA trial for PAH. The main event comes with its topline results in Q4 2025. GOSS’s pipeline includes a PH-ILD program slated to start Phase 3 in mid-2025. This program addresses a larger, high-mortality TAM.
Is It Worth Investing in Gossamer Bio Inc (NASDAQ: GOSS) Right Now?
Moreover, the 36-month beta value for GOSS is 1.90. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for GOSS is 182.10M and currently, short sellers hold a 3.14% of that float. On March 05, 2025, GOSS’s average trading volume was 1.68M shares.
GOSS’s Market Performance
The stock of Gossamer Bio Inc (GOSS) has seen a -5.47% decrease in the past week, with a 19.31% rise in the past month, and a 76.03% gain in the past quarter. The volatility ratio for the week is 10.81%, and the volatility levels for the past 30 days are at 11.59% for GOSS. The simple moving average for the past 20 days is -2.35% for GOSS’s stock, with a 34.89% simple moving average for the past 200 days.
Analysts’ Opinion of GOSS
Many brokerage firms have already submitted their reports for GOSS stocks, with Oppenheimer repeating the rating for GOSS by listing it as a “Outperform.” The predicted price for GOSS in the upcoming period, according to Oppenheimer is $9 based on the research report published on June 25, 2024 of the previous year 2024.
Wedbush, on the other hand, stated in their research note that they expect to see GOSS reach a price target of $4. The rating they have provided for GOSS stocks is “Outperform” according to the report published on April 05th, 2024.
UBS gave a rating of “Neutral” to GOSS, setting the target price at $1.25 in the report published on July 27th of the previous year.
GOSS Trading at 15.25% from the 50-Day Moving Average
After a stumble in the market that brought GOSS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.19% of loss for the given period.
Volatility was left at 11.59%, however, over the last 30 days, the volatility rate increased by 10.81%, as shares surge +18.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +50.63% upper at present.
During the last 5 trading sessions, GOSS fell by -7.31%, which changed the moving average for the period of 200-days by +62.36% in comparison to the 20-day moving average, which settled at $1.2572. In addition, Gossamer Bio Inc saw 35.85% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GOSS starting from Aranda Richard, who sale 1,908 shares at the price of $0.66 back on Jun 24 ’24. After this action, Aranda Richard now owns 196,891 shares of Gossamer Bio Inc, valued at $1,260 using the latest closing price.
Hasnain Faheem, the President & CEO of Gossamer Bio Inc, purchase 372,000 shares at $0.67 during a trade that took place back on Jun 21 ’24, which means that Hasnain Faheem is holding 5,408,073 shares at $250,282 based on the most recent closing price.
Stock Fundamentals for GOSS
Current profitability levels for the company are sitting at:
- -0.56 for the present operating margin
- 0.97 for the gross margin
The net margin for Gossamer Bio Inc stands at -0.64. The total capital return value is set at -0.21. Equity return is now at value -90.26, with -20.51 for asset returns.
Based on Gossamer Bio Inc (GOSS), the company’s capital structure generated 0.79 points at debt to capital in total, while cash flow to debt ratio is standing at -0.01. The debt to equity ratio resting at 3.76. The interest coverage ratio of the stock is -5.23.
Currently, EBITDA for the company is -172.15 million with net debt to EBITDA at -3.09. When we switch over and look at the enterprise to sales, we see a ratio of 4.13. The receivables turnover for the company is 17.02for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.74.
Conclusion
To wrap up, the performance of Gossamer Bio Inc (GOSS) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
